Warning: Undefined variable $zfal in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Deprecated: str_replace(): Passing null to parameter #3 ($subject) of type array|string is deprecated in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 525
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 530
 free
Warning: Undefined variable $sterm in C:\Inetpub\vhosts\kidney.de\httpdocs\mlpefetch.php on line 531
 free
 free
 
English Wikipedia
Nephropedia Template TP (
Twit Text
DeepDyve
Pubget Overpricing |  
lüll
A major role for RCAN1 in atherosclerosis progression Mendez-Barbero N; Esteban V; Villahoz S; Escolano A; Urso K; Alfranca A; Rodriguez C; Sanchez SA; Osawa T; Andres V; Martinez-Gonzalez J; Minami T; Redondo JM; Campanero MREMBO Mol Med 2013[Dec]; 5 (12): 1901-17Atherosclerosis is a complex inflammatory disease involving extensive vascular vessel remodelling and migration of vascular cells. As RCAN1 is implicated in cell migration, we investigated its contribution to atherosclerosis. We show RCAN1 induction in atherosclerotic human and mouse tissues. Rcan1 was expressed in lesional macrophages, endothelial cells and vascular smooth muscle cells and was induced by treatment of these cells with oxidized LDLs (oxLDLs). Rcan1 regulates CD36 expression and its genetic inactivation reduced atherosclerosis extension and severity in Apoe(-/-) mice. This effect was mechanistically linked to diminished oxLDL uptake, resistance to oxLDL-mediated inhibition of macrophage migration and increased lesional IL-10 and mannose receptor expression. Moreover, Apoe(-/-) Rcan1(-/-) macrophages expressed higher-than-Apoe(-/-) levels of anti-inflammatory markers. We previously showed that Rcan1 mediates aneurysm development and that its expression is not required in haematopoietic cells for this process. However, transplantation of Apoe(-/-) Rcan1(-/-) bone-marrow (BM) cells into Apoe(-/-) recipients confers atherosclerosis resistance. Our data define a major role for haematopoietic Rcan1 in atherosclerosis and suggest that therapies aimed at inhibiting RCAN1 expression or function might significantly reduce atherosclerosis burden.|Aneurysm/metabolism/pathology[MESH]|Animals[MESH]|Apolipoproteins E/deficiency/genetics/metabolism[MESH]|Atherosclerosis/metabolism/*pathology[MESH]|Bone Marrow Cells/cytology/metabolism[MESH]|Bone Marrow Transplantation[MESH]|CD36 Antigens/genetics/metabolism[MESH]|Calcium-Binding Proteins[MESH]|Cell Movement/drug effects[MESH]|Disease Progression[MESH]|Endothelial Cells/cytology/drug effects/metabolism[MESH]|Foam Cells/cytology[MESH]|Humans[MESH]|Intracellular Signaling Peptides and Proteins/deficiency/genetics/*metabolism[MESH]|Lipoproteins, LDL/toxicity[MESH]|Macrophages/cytology/drug effects/metabolism[MESH]|Mice[MESH]|Mice, Knockout[MESH]|Muscle Proteins/deficiency/genetics/*metabolism[MESH]|Muscle, Smooth, Vascular/cytology/drug effects/metabolism[MESH]|Phenotype[MESH] |
